Updated:
Vividion Therapeutics
Vividion's chemoproteomics platform turns the human proteome into a target map, producing clinical-stage candidates against historically undruggable...
Vividion Therapeutics
Vividion Therapeutics operates a proprietary drug-discovery engine built on chemoproteomics, a technique that interrogates protein binding across the human proteome at scale. Its platform identifies functional, often novel, binding pockets on disease-relevant proteins and advances covalent small molecules against those targets. This positions Vividion to address historically 'undruggable' targets, a category that the wider pharmaceutical industry has largely deprioritized for lack of viable chemical starting points. The firm's pipeline spans oncology and, based on its disclosed platform capabilities, likely extends to inflammatory and neurological indications. Its most advanced public program is VVD-214, a covalent allosteric inhibitor of the WRN helicase for microsatellite-instability-high cancers. Vividion published preclinical characterization of VVD-214 in the Journal of Medicinal Chemistry in January 2026, concurrently disclosing its advancement into clinical trials. A separate program targets KEAP1, a first-in-class activator that the firm described in a December 2025 press release, with clinical activity underway in oncology. The geographic footprint is concentrated at its San Diego headquarters. Vividion's scale is opaque; headcount, total capital deployed, and leadership are undisclosed on publicly indexed materials. The firm's most recent dated operational signal is the January 2026 clinical and publication milestone for its WRN inhibitor, as reported on its corporate news feed. As of mid-2026, no affiliated investment vehicles, philanthropic foundations, or real-asset arms are publicly linked to the entity. Vividion's structural differentiator is its integration of chemical biology with therapeutic development without an external discovery-outsourcing model. Rather than licensing early-stage hits from academic labs, the firm's chemoproteomic platform generates proprietary starting points internally. For institutional allocators, investment access would likely route through venture capital syndicates or parent-company structures, as Vividion operates as a standalone therapeutics company, not a multi-asset family office or fund manager.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
How does Vividion's chemoproteomics platform differ from conventional drug discovery?
Conventional high-throughput screening tests compounds against an isolated protein target. Vividion's platform instead exposes covalent small-molecule fragments to the entire proteome in live cells, then uses mass spectrometry to identify which proteins — and which specific binding pockets — were engaged. This functional readout reveals druggable sites that structural biology alone would miss, allowing the team to prosecute targets with no known small-molecule binders. The result is a proprietary chemical starting point that maps directly to a disease-relevant mechanism.
What is VVD-214 and why does its mechanism matter?
VVD-214 is a covalent allosteric inhibitor of the WRN helicase. WRN is a synthetic-lethal target in microsatellite-instability-high tumors, meaning cancer cells that rely on WRN for survival cannot compensate when the protein is blocked. Vividion published the discovery and preclinical characterization of VVD-214 in January 2026, confirming its clinical-stage advancement (per Journal of Medicinal Chemistry, 2026). Allosteric inhibition offers a selectivity advantage over orthosteric approaches, reducing off-target toxicity in a target class where ATP-competitive inhibitors have historically struggled.
Does Vividion operate as a family office or an investment manager?
No. Vividion Therapeutics is a biopharmaceutical operating company, not a family office, fund, or pooled investment vehicle. Its value to institutional allocators comes from equity positions in private financing rounds — typically accessible through venture capital syndicates or corporate-parent structures. It does not manage third-party capital or function as an asset manager, and it has no disclosed family-wealth backing that would classify it as a single-family office.
What is Vividion's posture on co-investments alongside external capital providers?
As an operating therapeutics company, Vividion does not formally syndicate co-investment rights the way a general partner would. External capital likely enters via equity raises led by venture firms or strategic pharmaceutical investors. The firm has not publicly disclosed a dedicated co-investment vehicle or a formal mechanism for limited partners to invest directly alongside its internal programs.
Which therapeutic areas does Vividion explicitly target?
Public disclosures confirm active programs in oncology, including the WRN helicase inhibitor VVD-214 in MSI-high tumors and a KEAP1 activator in clinical development. Vividion's platform narrative emphasizes historically undruggable targets across many disease areas, which suggests additional undisclosed programs may exist in inflammation, neurology, or metabolic disease. However, only oncology programs have been named in corporate publications as of mid-2026.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: